Market News
Stay updated with the latest market trends, earnings, and economic indicators.
SBI in $1 billion funding for Sun Pharma’s US deal
State Bank of India is set to commit up to $1 billion to fund Sun Pharmaceutical Industries Ltd.'s $12 billion acquisition of Organon & Co. This move marks a significant step for government-run banks in financing corporate takeovers. SBI will join other global lenders in this substantial deal. The funding underscores the growing ambition of Indian companies to expand globally.
Dr. Agarwal's Shares May Rally 35% on Strong Surgical Growth, Says Motilal Oswal — Check Target Price
Motilal Oswal remains bullish on Dr. Agarwal's structural growth story, backed by its leadership in the eye-care segment and a rapidly scaling surgical franchise.
7 most valued firms' mcap eroded ₹1.25 trn last week, RIL took biggest hit
The combined market valuation of seven of the top-10 most-valued firms eroded by Rs 1.25 lakh crore last week, with Reliance Industries taking the biggest hit, in-line with a bearish trend in equities. Last week, the BSE benchmark Sensex declined 532.4 points, or 0.71 per cent, and the NSE Nifty dipped 181.05 points, or 0.76 per cent. "Persistent FII selling remained the key drag on market sentiment despite supportive developments such as cooling crude oil prices and a recovery in the rupee against the US dollar. Concerns regarding the pace of monsoon advancement also weighed on investor confidence," Santosh Meena, Head of Research at Swastika Investmart Ltd, said. From the top-10 pack, Reliance Industries, Bharti Airtel, Tata Consultancy Services (TCS), Bajaj Finance, Larsen & Toubro, Life Insurance Corporation of India (LIC) and Hindustan Unilever faced erosion from their valuation, while HDFC Bank, ICICI Bank, and State Bank of India were the gainers. The market valuation of ...
Shares to buy or sell: Chandan Taparia of Motilal Oswal recommends 3 stocks to buy today amid RBI policy - 5 June 2026
Shares to buy or sell: Chandan Taparia has recommended three stocks to buy today, 5 June 2026 - BSE, Laurus Labs and Exide Industries shares.
Shares to buy or sell: Chandan Taparia of Motilal Oswal recommends three stocks to buy today - 2 June 2026 - Mint
Shares to buy or sell: Chandan Taparia of Motilal Oswal recommends three stocks to buy today - 2 June 2026Mint
Blue Jet Healthcare gains 8% post Q4; analysts split on near-term prospects
Emkay Global has retained its 'Reduce' rating, while Motilal Oswal has maintained its 'Buy' stance, reflecting contrasting expectations on recovery in key business segments and the margin trajectory
Shares to buy or sell: Chandan Taparia of Motilal Oswal recommends three stocks to buy today - 26 May 2026 - Mint
Shares to buy or sell: Chandan Taparia of Motilal Oswal recommends three stocks to buy today - 26 May 2026Mint
Sun Pharma Shares In Focus As Motilal Oswal Retains Bullish Call After Q4 — Check Target Price, Upside
Sun Pharma delivered in-line revenue in Q4, whereas Ebitda/PAT came in lower than expected, dragged down by higher marketing spending and lower milestone income.
Cotec Healthcare, Deepa Jewellers receive SEBI's nod to float IPOs
Cotec Healthcare and Deepa Jewellers get SEBI approval for IPOs, plan fresh issues and OFS to fund capacity expansion, working capital and general corporate needs, to list on BSE and NSE
Shares to buy or sell: Chandan Taparia of Motilal Oswal recommends three stocks to buy today - 22 May 2026 - Mint
Shares to buy or sell: Chandan Taparia of Motilal Oswal recommends three stocks to buy today - 22 May 2026Mint
Zydus Lifesciences shares soar 7% to fresh record high after Q4 results. Should you buy, sell or hold?
Zydus Lifesciences shares climbed to a new 52-week high. The company reported a 9% rise in net profit and over 16% revenue growth for the January-March quarter. A Rs 1,100 crore share buyback was announced. Analysts from Nomura, Nuvama, Motilal Oswal, and JM Financial shared their views on the company's performance and future prospects.
Zydus LifeSciences Shares in Focus: Motilal Oswal Maintains Neutral Rating on Limited Upside — Check Revised Target Price
The current valuation provides limited upside and hence, Motilal Oswal has maintained Neutral rating on Zydus Lifesciences.